179 related articles for article (PubMed ID: 38654326)
1. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
2. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
4. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy.
Vervuurt M; Kuiperij HB; de Kort AM; Kersten I; Klijn CJM; Schreuder FHBM; Verbeek MM
Alzheimers Res Ther; 2024 May; 16(1):108. PubMed ID: 38745197
[TBL] [Abstract][Full Text] [Related]
5. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.
van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM
Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chain predicts risk of recurrence in cerebral amyloid angiopathy-related intracerebral hemorrhage.
Cheng X; Su Y; Wang Q; Gao F; Ye X; Wang Y; Xia Y; Fu J; Shen Y; Al-Shahi Salman R; Dong Q
Aging (Albany NY); 2020 Nov; 12(23):23727-23738. PubMed ID: 33221749
[TBL] [Abstract][Full Text] [Related]
7. NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease.
Wilms AE; de Boer I; Pelzer N; In't Veld SGJG; Middelkoop HAM; Teunissen CE; Terwindt GM
J Neurol; 2024 Apr; ():. PubMed ID: 38581544
[TBL] [Abstract][Full Text] [Related]
8. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
9. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
[TBL] [Abstract][Full Text] [Related]
10. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
12. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
14. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia.
Heller C; Foiani MS; Moore K; Convery R; Bocchetta M; Neason M; Cash DM; Thomas D; Greaves CV; Woollacott IO; Shafei R; Van Swieten JC; Moreno F; Sanchez-Valle R; Borroni B; Laforce R; Masellis M; Tartaglia MC; Graff C; Galimberti D; Rowe JB; Finger E; Synofzik M; Vandenberghe R; de Mendonca A; Tagliavini F; Santana I; Ducharme S; Butler CR; Gerhard A; Levin J; Danek A; Frisoni G; Sorbi S; Otto M; Heslegrave AJ; Zetterberg H; Rohrer JD;
J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):263-270. PubMed ID: 31937580
[TBL] [Abstract][Full Text] [Related]
15. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability.
Simrén J; Weninger H; Brum WS; Khalil S; Benedet AL; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2022 Oct; 18(10):1988-1992. PubMed ID: 36102852
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
17. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
[TBL] [Abstract][Full Text] [Related]
19. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
